|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 9 (November 1), 1999:
pp. 3114-3120
Clinicopathogenetic Significance of Chromosomal Abnormalities in
Patients With Blastic Peripheral B-Cell Lymphoma
Brigitte Schlegelberger,
Thomas Zwingers,
Lana Harder,
Hadwiga Nowotny,
Reiner Siebert,
Michael Vesely,
Heinrich Bartels,
Ruth Sonnen,
Georg Hopfinger,
Alexander Nader,
German Ott,
Konrad Müller-Hermelink,
Alfred Feller, and
Renate Heinz for the
Kiel-Wien-Lymphoma Study Group
From the Department of Human Genetics, University of Kiel; Estimate
GmbH, Augsburg; Germany; Ludwig-Boltzmann Institute for Leukemia
Research and Hematology, Third Medical Department and the Department of
Pathology, Hanusch Hospital, Vienna, Austria; Jakob Erdheim Institute
for Pathology and Clinical Bacteriology, Lainz Hospital, Vienna,
Austria; Municipal Hospital, Lübeck, Germany; Hospital St Georg,
Hamburg, Germany; the Department of Pathology, Hanusch Hospital,
Vienna, Austria; the Department of Pathology, University of
Würzburg, Germany; and the Department of Pathology, Medical
University of Lübeck, Germany.
So far, reproducible histomorphologic and immunological criteria to
distinguish clinicopathologic subtypes of blastic peripheral B-cell
non-Hodgkin's lymphoma (BBCL), especially centroblastic (cb) and
immunoblastic (ib) lymphomas, for daily diagnostic use are still
lacking. Therefore, we correlated the cytogenetic findings in 126 patients with BBCL with histopathologic diagnoses. Subclassification of
cb and ib lymphomas relied on the criteria defined in the updated Kiel
classification; these subtypes are also listed in the Revised European-American Lymphoma (REAL) classification and in a
preliminary report on the newly established World Health
Organization classification, to investigate their clinical
significance. Moreover, we performed a multivariate analysis to compare
the prognostic significance of cytogenetic findings with the
International Index. There were significant differences in the
frequency of chromosome aberrations between different BBCL subtypes:
t(8;14) was predominantly present in Burkitt's lymphomas, t(14;18) in
centroblastic lymphomas, deletions in 8q and 14q, changes of 4q and
losses of chromosome 10 in immunoblastic lymphomas; t(11;14) was
restricted to blastoid mantle cell lymphomas and associated with a poor
prognosis. In cb lymphomas, deletions in 1q42-qter, duplications in
1q23-32, trisomy 5, and changes of 15q were identified as independent
prognostic factors. In ib lymphomas, changes of 7q and 8q had stronger
impact on survival than the International Index. These findings
underline that Burkitt's, cb, ib, and blastoid mantle-cell lymphoma
are biologically distinct and clinically relevant entities and that
cytogenetic findings can be helpful to subtype BBCL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Ghesquieres, F. Berger, P. Felman, E. Callet-Bauchu, P.-A. Bryon, A. Traverse-Glehen, C. Thieblemont, L. Baseggio, A.-S. Michallet, B. Coiffier, et al.
Clinicopathologic Characteristics and Outcome of Diffuse Large B-Cell Lymphomas Presenting With an Associated Low-Grade Component at Diagnosis
J. Clin. Oncol.,
November 20, 2006;
24(33):
5234 - 5241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Oschlies, W. Klapper, M. Zimmermann, M. Krams, H.-H. Wacker, B. Burkhardt, L. Harder, R. Siebert, A. Reiter, and R. Parwaresch
Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial
Blood,
May 15, 2006;
107(10):
4047 - 4052.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bea, A. Zettl, G. Wright, I. Salaverria, P. Jehn, V. Moreno, C. Burek, G. Ott, X. Puig, L. Yang, et al.
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
Blood,
November 1, 2005;
106(9):
3183 - 3190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bea, L. Colomo, A. Lopez-Guillermo, I. Salaverria, X. Puig, M. Pinyol, S. Rives, E. Montserrat, and E. Campo
Clinicopathologic Significance and Prognostic Value of Chromosomal Imbalances in Diffuse Large B-Cell Lymphomas
J. Clin. Oncol.,
September 1, 2004;
22(17):
3498 - 3506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Katzenberger, G. Ott, T. Klein, J. Kalla, H. K. Muller-Hermelink, and M. M. Ott
Cytogenetic Alterations Affecting BCL6 Are Predominantly Found in Follicular Lymphomas Grade 3B with a Diffuse Large B-Cell Component
Am. J. Pathol.,
August 1, 2004;
165(2):
481 - 490.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Katzenberger, A. Lohr, S. Schwarz, M. Dreyling, J. Schoof, C. Nickenig, S. Stilgenbauer, J. Kalla, M. M. Ott, H. K. Muller-Hermelink, et al.
Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell
Blood,
January 15, 2003;
101(2):
699 - 702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Tort, S. Hernandez, S. Bea, A. Martinez, M. Esteller, J. G. Herman, X. Puig, E. Camacho, M. Sanchez, I. Nayach, et al.
CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas
Blood,
December 15, 2002;
100(13):
4602 - 4608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ott, T. Katzenberger, A. Lohr, S. Kindelberger, T. Rudiger, M. Wilhelm, J. Kalla, A. Rosenwald, J. G. Muller, M. M. Ott, et al.
Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3
Blood,
May 15, 2002;
99(10):
3806 - 3812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Nanjangud, P. H. Rao, A. Hegde, J. Teruya-Feldstein, G. Donnelly, J. Qin, S. C. Jhanwar, A. D. Zelenetz, and R. S. K. Chaganti
Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma
Blood,
April 1, 2002;
99(7):
2554 - 2561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Itoyama, R. S. K. Chaganti, Y. Yamada, K. Tsukasaki, S. Atogami, H. Nakamura, M. Tomonaga, K. Ohshima, M. Kikuchi, and N. Sadamori
Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki
Blood,
June 1, 2001;
97(11):
3612 - 3620.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. O'Brien, H. Kantarjian, D. A. Thomas, F. J. Giles, E. J. Freireich, J. Cortes, S. Lerner, and M. J. Keating
Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
April 15, 2001;
19(8):
2165 - 2170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. T. Aguiar, Y. Yakushijin, S. Kharbanda, R. Salgia, J. A. Fletcher, and M. A. Shipp
BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration
Blood,
December 15, 2000;
96(13):
4328 - 4334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
